All In Biotech

NDA 205555 · Novatech SA

Steritalc

Talc · Intrapleural

Orphan

Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

May 1, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

48

15 Phase 3, 3 recruiting

FAERS reports

420

411 serious, 108 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 25, 2025.

1.INDICATIONS AND USAGE 1.INDICATIONS AND USAGE 1.1 Malignant Pleural Effusion STERITALC is indicated to decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion. 1.2 Pneumothorax STERITALC is indicated in adults to decrease the recurrence of pneumothorax. ___________ INDICATIONS AND USAGE__ __________ STERITALC® is a sclerosing agent indicated: To decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion. (1.1) In adults to decrease the recurrence of pneumothorax. (1.2)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 1, 2017 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
3 products under this application
  • STERITALC · TALC 4GM/VIAL · POWDER, INTRAPLEURAL · Prescription
  • STERITALC · TALC 2GM/VIAL · POWDER, INTRAPLEURAL · Prescription
  • STERITALC · TALC 3GM/VIAL · POWDER, INTRAPLEURAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Talc" as an intervention, any sponsor and status, largest first.

All 48 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • exposure to chemical pollution305
  • pain257
  • anxiety222
  • injury198
  • mesothelioma176
  • disability130
  • emotional distress92
  • quality of life decreased86
  • deformity78
  • mesothelioma malignant57
  • epithelioid mesothelioma38
  • pleural mesothelioma malignant28

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20072
20091
20112
20121
20145
20151
20167
20174
20188
20194
20201
202117
20224
202374
2024283
20254
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 146 on PubMed

Sponsor: Novatech SA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.